Jul 23 at 10:52 AM
๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $Eli Lilly(LLY.US) Eli Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐๐น๐ถ ๐๐ถ๐น๐น๐ reports positive ๐ฃ๐ต๐ฎ๐๐ฒ ๐ฏ results for retatrutide.โค ๐ง๐ฅ๐๐จ๐ ๐ฃ๐-๐ฎ achieved average ๐ฎ๐ฌ.๐ด% (๐ฐ๐ต.๐ฒ ๐น๐ฏ๐) weight loss at ๐ญ๐ฎ mg.โค Placebo group lost ๐ฐ.๐ฌ% (๐ต.๐ฏ ๐น๐ฏ๐) in ๐ง๐ฅ๐๐จ๐ ๐ฃ๐-๐ฎ.โค ๐๐ญ๐ declined by up to ๐ญ.๐ฒ% from a ๐ณ.๐ณ% baseline.โค ๐ง๐ฅ๐๐จ๐ ๐ฃ๐-๐ฏ achieved average ๐ฎ๐ฎ.๐ฒ% (๐ฑ๐ฑ.๐ด ๐น๐ฏ๐) weight loss at ๐ญ๐ฎ mg.โค Retatrutide reduced triglycerides by ๐ฏ๐ณ.๐ฌ%, non-HDL cholesterol by ๐ญ๐ฒ.๐ฑ%.โค Systolic blood pressure declined by an average of ๐ต.๐ฏ mmHg.โค ๐ ๐๐๐ analyses did not reach statistical significance as confidence intervals crossed ๐ญ.๐ฌ.โค Lilly plans to submit an ๐๐๐ Biologics License Application in ๐ค๐ญ ๐ฎ๐ฌ๐ฎ๐ณ.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.